

Peter S Hall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/485990/publications.pdf>

Version: 2024-02-01

99
papers

3,342
citations

236612

25
h-index

161609

54
g-index

111
all docs

111
docs citations

111
times ranked

5563
citing authors

#	ARTICLE	IF	CITATIONS
1	PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 1444-1454.	13.9	503
2	Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 933-942.	5.1	370
3	Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 423-433.	0.8	240
4	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. <i>Lancet</i> , The, 2019, 393, 2599-2612.	6.3	225
5	Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw050.	3.0	166
6	PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. <i>Immunotherapy</i> , 2017, 9, 499-506.	1.0	162
7	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	5.1	148
8	Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer. <i>JAMA Oncology</i> , 2021, 7, 869.	3.4	83
9	The 4 "A"s test for detecting delirium in acute medical patients: a diagnostic accuracy study. <i>Health Technology Assessment</i> , 2019, 23, 1-194.	1.3	82
10	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
11	Economic Evaluation of Genomic Test-Directed Chemotherapy for Early-Stage Lymph Node-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 56-66.	3.0	75
12	Cost Effectiveness Modelling for Health Technology Assessment. , 2015, , .		53
13	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-202.	1.3	53
14	PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. <i>Health Technology Assessment</i> , 2017, 21, 1-122.	1.3	52
15	Current perspective " Trastuzumab. <i>European Journal of Cancer</i> , 2009, 45, 12-18.	1.3	51
16	The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 108-120.	2.4	49
17	Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer. <i>Pharmacoeconomics</i> , 2011, 29, 415-432.	1.7	48
18	Sharing Risk between Payer and Provider by Leasing Health Technologies: An Affordable and Effective Reimbursement Strategy for Innovative Technologies?. <i>Value in Health</i> , 2014, 17, 438-444.	0.1	41

#	ARTICLE	IF	CITATIONS
19	Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. <i>Cancer</i> , 2012, 118, 3920-3927.	2.0	40
20	One-year resource utilisation, costs and quality of life in patients with acute respiratory distress syndrome (ARDS): secondary analysis of a randomised controlled trial. <i>Journal of Intensive Care</i> , 2016, 4, 56.	1.3	40
21	Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 5.	0.6	40
22	Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial. <i>Clinical Oncology</i> , 2013, 25, 109-116.	0.6	37
23	Independent validation of the PREDICT breast cancer prognosis prediction tool in 45,789 patients using Scottish Cancer Registry data. <i>British Journal of Cancer</i> , 2018, 119, 808-814.	2.9	37
24	A randomised controlled trial and cost-effectiveness analysis of high-frequency oscillatory ventilation against conventional artificial ventilation for adults with acute respiratory distress syndrome. The OSCAR (OSCillation in ARDS) study. <i>Health Technology Assessment</i> , 2015, 19, 1-178.	1.3	34
25	One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit. <i>Pharmacoeconomics</i> , 2020, 38, 135-141.	1.7	32
26	Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. <i>Value in Health</i> , 2017, 20, 1311-1318.	0.1	31
27	Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. <i>British Journal of Cancer</i> , 2020, 123, 852-859.	2.9	30
28	Expected Net Present Value of Sample Information. <i>Medical Decision Making</i> , 2012, 32, E11-E21.	1.2	27
29	SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer considered to be at higher risk of complications from surgical resection. <i>European Respiratory Journal</i> , 2020, 56, 2000118.	3.1	27
30	The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisation. <i>Health Technology Assessment</i> , 2018, 22, 1-274.	1.3	27
31	The economic burden of cancer in the UK: a study of survivors treated with curative intent. <i>Psycho-Oncology</i> , 2016, 25, 77-83.	1.0	24
32	Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?. <i>Pharmacoeconomics</i> , 2013, 31, 731-737.	1.7	23
33	Healthcare trajectories and costs in the last year of life: a retrospective primary care and hospital analysis. <i>BMJ Supportive and Palliative Care</i> , 2020, , bmjspcare-2020-002630.	0.8	23
34	Early Economic Evaluation of Diagnostic Technologies: Experiences of the NIHR Diagnostic Evidence Co-operatives. <i>Medical Decision Making</i> , 2019, 39, 857-866.	1.2	22
35	The impact of COVID-19 on systemic anticancer treatment delivery in Scotland. <i>British Journal of Cancer</i> , 2021, 124, 1353-1356.	2.9	22
36	Toward a Framework for Outcome-Based Analytical Performance Specifications: A Methodology Review of Indirect Methods for Evaluating the Impact of Measurement Uncertainty on Clinical Outcomes. <i>Clinical Chemistry</i> , 2019, 65, 1363-1374.	1.5	21

#	ARTICLE	IF	CITATIONS
37	Evidence on the economic value of end-of-life and palliative care interventions: a narrative review of reviews. <i>BMC Palliative Care</i> , 2021, 20, 89.	0.8	20
38	Health economics in drug development: Efficient research to inform healthcare funding decisions. <i>European Journal of Cancer</i> , 2010, 46, 2674-2680.	1.3	14
39	Chemotherapy effectiveness in trial-underrepresented groups with early breast cancer: A retrospective cohort study. <i>PLoS Medicine</i> , 2019, 16, e1003006.	3.9	14
40	Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy. <i>Clinical Oncology</i> , 2020, 32, 292-297.	0.6	14
41	Factors Predicting Outcome for Advanced Gastroesophageal Cancer in Elderly Patients Receiving Palliative Chemotherapy. <i>Clinical Oncology</i> , 2010, 22, 107-113.	0.6	13
42	NETIMIS: Dynamic Simulation of Health Economics Outcomes Using Big Data. <i>Pharmacoeconomics</i> , 2016, 34, 107-114.	1.7	13
43	Real-world data for efficient health technology assessment. <i>European Journal of Cancer</i> , 2017, 79, 235-237.	1.3	12
44	Distinguishing between direct and indirect consequences of covid-19. <i>BMJ, The</i> , 2020, 369, m2377.	3.0	12
45	Healthcare use and costs in the last year of life: a national population data linkage study. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjpspcare-2020-002708.	0.8	12
46	Six versus 12 monthsâ€™ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-190.	1.3	11
47	Intensity of care in cancer patients in the last year of life: a retrospective data linkage study. <i>British Journal of Cancer</i> , 2022, 127, 712-719.	2.9	10
48	Factors affecting hospital costs in lung cancer patients in the United Kingdom. <i>Lung Cancer</i> , 2016, 97, 8-14.	0.9	9
49	Variable and fixed costs in NHS radiotherapy; consequences for increasing hypo fractionation. <i>Radiotherapy and Oncology</i> , 2022, 166, 180-188.	0.3	9
50	Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer. <i>Journal of Medical Economics</i> , 2022, 25, 591-604.	1.0	9
51	Non-cancer medications for patients with incurable cancer: time to stop and think?. <i>British Journal of General Practice</i> , 2010, 60, 243-244.	0.7	8
52	Data Resource Profile: The COloRECTal cancer data repository (CORECT-R). <i>International Journal of Epidemiology</i> , 2021, 50, 1418-1418k.	0.9	8
53	Frailty and treatment outcome in advanced gastro-oesophageal cancer: An exploratory analysis of the CO2 trial. <i>Journal of Geriatric Oncology</i> , 2022, 13, 287-293.	0.5	8
54	The cost of ignoring acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1270-1272.	0.4	7

#	ARTICLE	IF	CITATIONS
55	A randomised, phase II, unblinded trial of an Exercise and Nutrition-based Rehabilitation programme (ENeRgy) versus standard care in patients with cancer: feasibility trial protocol. Pilot and Feasibility Studies, 2018, 4, 192.	0.5	7
56	Real-world evidence was feasible for estimating effectiveness of chemotherapy in breast cancer: a cohort study. Journal of Clinical Epidemiology, 2019, 109, 125-132.	2.4	7
57	Real-world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review). International Journal of Oncology, 2021, 58, .	1.4	7
58	Severe Epistaxis with Tyrosine Kinase Inhibitors. Clinical Oncology, 2008, 20, 318-319.	0.6	6
59	Concomitant medications in cancer patients: should we be more active in their management?. Annals of Oncology, 2010, 21, 430.	0.6	6
60	What Evidence Is There for the Reimbursement of Personalised Medicine?. Pharmacoeconomics, 2013, 31, 181-183.	1.7	6
61	The investigative burden of membranous nephropathy in the UK. CKJ: Clinical Kidney Journal, 2020, 13, 27-34.	1.4	6
62	Lapatinib for inflammatory breast cancer. Lancet Oncology, The, 2009, 10, 538-539.	5.1	5
63	Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin. Pharmacoeconomics, 2014, 32, 327-334.	1.7	5
64	On Predicting the Outcomes of Chemotherapy Treatments in Breast Cancer. Lecture Notes in Computer Science, 2019, , 180-190.	1.0	5
65	Rationale and study design: A randomized controlled trial of early palliative care in newly diagnosed cancer patients in Addis Ababa, Ethiopia. Contemporary Clinical Trials Communications, 2020, 18, 100564.	0.5	5
66	Incompatible: end-of-life care and health economics. BMJ Supportive and Palliative Care, 2021, 11, 296-298.	0.8	5
67	Creation of the first national linked colorectal cancer dataset in Scotland: prospects for future research and a reflection on lessons learned. International Journal of Population Data Science, 2021, 6, 1654.	0.1	4
68	PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT).. Journal of Clinical Oncology, 2015, 33, 6009-6009.	0.8	4
69	Are we representing the true population in oncology trials?. Annals of Oncology, 2009, 20, 2022.	0.6	3
70	Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal cancer (aGOAC): The uncertain randomization of the GO2 phase III trial.. Journal of Clinical Oncology, 2019, 37, 4051-4051.	0.8	3
71	Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype. Breast Cancer Research and Treatment, 0, , .	1.1	3
72	OPTIMA: a prospective randomised trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions. European Journal of Surgical Oncology, 2016, 42, S229.	0.5	2

#	ARTICLE	IF	CITATIONS
73	Accurate Measurement of Financial Toxicity Is a Prerequisite to Finding a Remedy. <i>Breast Care</i> , 2017, 12, 78-80.	0.8	2
74	Health economic studies of colorectal cancer and the contribution of administrative data: A systematic review. <i>European Journal of Cancer Care</i> , 2021, 30, e13477.	0.7	2
75	The Finding My Way UK Clinical Trial: Adaptation Report and Protocol for a Replication Randomized Controlled Efficacy Trial of a Web-Based Psychological Program to Support Cancer Survivors. <i>JMIR Research Protocols</i> , 2021, 10, e31976.	0.5	2
76	How can early stage economic evaluation help guide research for future vaccines?. <i>Vaccine</i> , 2021, 40, 175-175.	1.7	2
77	Stopping Tamoxifen after 5 Years of Therapy for Early Breast Cancer: Does it Alter Quality of Life?. <i>Clinical Oncology</i> , 2011, 23, 652.	0.6	1
78	Efficient design of a phase III trial of competing tests for personalised cancer treatment in the absence of gold standard outcome data: challenges and potential solutions. <i>Trials</i> , 2013, 14, .	0.7	1
79	Role of derived neutrophil lymphocyte ratio as a biomarker in advanced colorectal cancer. <i>Lancet, The</i> , 2014, 383, S96.	6.3	1
80	1809 Results of the OPTIMA (Optimal Personalized Treatment of early breast cancer using Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 To	1.3	1
81	Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)?. <i>Cancer Investigation</i> , 2015, 33, 347-353.	0.6	1
82	Fractionation and early mortality in palliative radiotherapy: Insights from the national radiotherapy dataset. <i>Clinical Oncology</i> , 2019, 31, e14.	0.6	1
83	Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier. <i>Pharmacoeconomics</i> , 2021, 39, 19-24.	1.7	1
84	Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Populationâ€”Reply. <i>JAMA Oncology</i> , 2021, 7, 1725.	3.4	1
85	Three, two, or one drug chemotherapy for frail or elderly patients with advanced gastroesophageal cancer (321GO): A feasibility study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 97-97.	0.8	1
86	Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study. <i>ESMO Open</i> , 2021, 6, 100331.	2.0	1
87	Lapatinib in the management of breast cancer. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 553-568.	0.2	0
88	S73â€¦Healthcare costs associated with lung cancer diagnosed at emergency hospitalisation. <i>Thorax</i> , 2015, 70, A43-A43.	2.7	0
89	The use of early decision modelling and value of information analysis in an adaptive trial design: results from the OPTIMA preliminary study. <i>Trials</i> , 2015, 16, .	0.7	0
90	Modelling cost-effectiveness and value of information in clinical trials to inform stop go decisions: results from the arctic study. <i>Trials</i> , 2015, 16, .	0.7	0

#	ARTICLE	IF	CITATIONS
91	Independent endpoint event review for the elimination of reporting bias in an open label phase III pharmaceutical trial. <i>Trials</i> , 2015, 16, .	0.7	0
92	Better Reimbursement Decision-Making Based on Expected Cost-Effectiveness: Using Value of Information Decision Analysis to Improve The Design and Efficacy of A Phase Iii Program for Erlotinib. <i>Value in Health</i> , 2015, 18, A700.	0.1	0
93	Metastatic bone disease: new quality performance indicator development. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-003025.	0.8	0
94	D-dimers as a tumor marker in GIST: Can it reduce the frequency of CT scanning in patients receiving palliative imatinib?. <i>Journal of Clinical Oncology</i> , 2012, 30, 119-119.	0.8	0
95	Systemic therapy for advanced colorectal cancer. , 2012, , 61-74.		0
96	OPTIMA prelim: Optimal personalized treatment of early breast cancer using multiparameter analysis: Preliminary study.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS665-TPS665.	0.8	0
97	Age as an independent predictor of chemotherapy treatment decisions in 20 common cancers.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9550-9550.	0.8	0
98	Abstract P6-08-11: UK OPTIMA-prelim study demonstrates economic value in more clinical evaluation of multi-parameter prognostic tests in early breast cancer. , 2015, , .		0
99	Is PET-CT guided management for patients with locally advanced head and neck squamous cell cancer (HNSCC) cost-effective? Results from a UK non-inferiority phase III randomized trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6010-6010.	0.8	0